Effect of oral immunotherapy of nuts in the treatment of type 1 allergy
Not Applicable
Completed
- Conditions
- Type 1 allergy with food.Dermatitis due to ingested foodL27.2
- Registration Number
- IRCT20240121060754N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Patients with type 1 allergy after eating nuts
Exclusion Criteria
Patients with cardiovascular diseases, diabetes
Patients with skin symptoms of chronic eczema or active allergic diseases such as asthma, allergic rhinitis and uncontrolled active atopic dermatitis
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie oral immunotherapy for nut-induced type 1 food allergies?
How does oral immunotherapy compare to epinephrine autoinjectors in managing nut allergy symptoms?
Which biomarkers are associated with successful oral immunotherapy outcomes in IgE-mediated nut allergies?
What are the potential adverse events of oral immunotherapy for L27.2 dermatitis in food allergy patients?
Are there combination therapies with oral immunotherapy for treating type 1 allergies to multiple food allergens?